Earnings Preannouncement for 2025
Filed with SSE · · 3 pages · Chinese
Hinova Pharmaceuticals, Inc. on 6ix
Earlier from Hinova Pharmaceuticals
- Announcement on Resolutions of the 16th Meeting of the 2nd Board of Directors
- Announcement on Resolutions of the 15th Meeting of the 2nd Board of Directors
- Announcement on the Voluntary Disclosure of the Inclusion of Deutenzalutamide Soft Capsules in the 2025 National Medical Insurance Drug Catalog
- Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer
- Announcement on Convening the Q3 2025 Performance Briefing
Later from Hinova Pharmaceuticals
- Announcement on the Company's Successful GMP Compliance Inspection and the Amendment of Its Drug Manufacturing License
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of Completion of Inclusion of All Participants in Phase IIa Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
- Announcement on Change of Sponsor Representative
- Notice on Convening the 2025 Annual General Meeting
Follow Hinova Pharmaceuticals into a list and get an email when it puts out news.
Follow Hinova Pharmaceuticals